BC Cancer’s Personalized OncoGenomics (POG) Program is a world-leading initiative applying whole-genome and transcriptome analysis (WGTA) to inform real-time treatment decisions for patients with advanced, hard-to-treat cancers. Using a mixed methods approach, Dr.
Maintain, update and expand cohorts and databases, in order to examine outcomes in more recent survivors, survivors with newer treatments, older survivors, and survivors with longer time since diagnosis; and to examine patterns of change over time.
Long-term health care utilization including costs, and quality measures of healthcare are examined among survivors of childhood, adolescent, and young adult cancers, for risk stratification into levels of vulnerable and underserved subpopulations for priority change. Personal, clinical (includin
We have launched a birth cohort study in China to support studies of early life exposure to pollutants and impact on chronic disease.
We previously identified that melatonin suppression in nightshift workers is associated with reduced capacity for repair of oxidative DNA damage, which may contribute to increased risks of cancer in this group.
The CIHR-funded Catalyst project applies a mixed methods approach to enhancing shared decision-making in context to the return of genetic test results for hereditary cancer syndromes.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.